Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$23.29
-8.0%
$16.93
$8.89
$26.66
$1.01BN/A548,486 shs968,562 shs
Envista Holdings Corporation stock logo
NVST
Envista
$21.07
-0.3%
$20.56
$14.22
$23.00
$3.50B0.992.48 million shs1.98 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$49.71
-2.9%
$76.37
$41.50
$90.32
$2.64B-2.711.20 million shs2.61 million shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$119.15
+4.3%
$115.93
$55.00
$169.29
$4.06B2.181.30 million shs703,137 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-4.17%+9.42%+48.53%+38.84%+2,530,999,900.00%
Envista Holdings Corporation stock logo
NVST
Envista
+0.32%-0.09%+2.20%+14.51%+8.78%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-4.57%-29.23%-28.56%-34.06%-3.16%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-0.24%+8.25%-10.40%-16.09%-24.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$23.29
-8.0%
$16.93
$8.89
$26.66
$1.01BN/A548,486 shs968,562 shs
Envista Holdings Corporation stock logo
NVST
Envista
$21.07
-0.3%
$20.56
$14.22
$23.00
$3.50B0.992.48 million shs1.98 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$49.71
-2.9%
$76.37
$41.50
$90.32
$2.64B-2.711.20 million shs2.61 million shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$119.15
+4.3%
$115.93
$55.00
$169.29
$4.06B2.181.30 million shs703,137 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-4.17%+9.42%+48.53%+38.84%+2,530,999,900.00%
Envista Holdings Corporation stock logo
NVST
Envista
+0.32%-0.09%+2.20%+14.51%+8.78%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-4.57%-29.23%-28.56%-34.06%-3.16%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-0.24%+8.25%-10.40%-16.09%-24.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
2.75
Moderate Buy$22.56-5.27% Downside
Envista Holdings Corporation stock logo
NVST
Envista
2.33
Hold$20.92-0.68% Downside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.08
Buy$115.09129.72% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.73
Moderate Buy$125.405.37% Upside

Current Analyst Ratings Breakdown

Latest BBNX, TMDX, NVST, and SLNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$155.00
9/10/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/4/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold$115.00
8/27/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$106.00
8/25/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
8/20/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$123.00
8/18/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$100.00 ➝ $110.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$97.00 ➝ $106.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$105.00 ➝ $110.00
8/1/2025
Envista Holdings Corporation stock logo
NVST
Envista
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$24.00 ➝ $25.00
(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$78.02M13.27N/AN/A($5.72) per share-4.16
Envista Holdings Corporation stock logo
NVST
Envista
$2.55B1.37$1.67 per share12.65$17.05 per share1.24
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$531.29M7.64$1.71 per share69.63$6.81 per share17.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$54.76MN/A0.00N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B$0.3265.9317.411.122.11%4.84%2.68%10/29/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.9361.2283.23N/A13.49%28.02%8.64%10/27/2025 (Estimated)

Latest BBNX, TMDX, NVST, and SLNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million
7/31/2025Q2 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.24$0.26+$0.02$0.16$638.21 million$682.10 million
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48$0.92+$0.44$0.92$146.64 million$157.37 million
7/29/2025Q2 2025
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
14.68
13.79
Envista Holdings Corporation stock logo
NVST
Envista
0.46
2.44
2.08
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
15.13
15.01
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.61
9.86
9.17

Institutional Ownership

CompanyInstitutional Ownership
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
Envista Holdings Corporation stock logo
NVST
Envista
N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
N/A
Envista Holdings Corporation stock logo
NVST
Envista
0.66%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
29443.47 millionN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
12,300166.18 million165.09 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3053.15 million49.74 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21034.09 million31.70 millionOptionable

Recent News About These Companies

TransMedics: Upcoming Trials Are Critical
Stifel Nicolaus Sticks to Its Hold Rating for TransMedics Group (TMDX)
TD Cowen Sticks to Its Buy Rating for TransMedics Group (TMDX)
TransMedics Group (NASDAQ:TMDX) Coverage Initiated at Stifel Nicolaus
TransMedics: Just Like The CEO, I'm Buying

New MarketBeat Followers Over Time

Media Sentiment Over Time

Beta Bionics stock logo

Beta Bionics NASDAQ:BBNX

$23.29 -2.02 (-7.98%)
As of 04:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Envista stock logo

Envista NYSE:NVST

$21.07 -0.06 (-0.28%)
Closing price 03:59 PM Eastern
Extended Trading
$21.34 +0.27 (+1.31%)
As of 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$49.71 -1.46 (-2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$49.92 +0.21 (+0.42%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$119.15 +4.86 (+4.25%)
Closing price 04:00 PM Eastern
Extended Trading
$119.02 -0.13 (-0.10%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.